Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research.
Pritumumab is effective in preventing tumor growth in nude mice but not in SCID mice[1].Pritumumab can limit the growth of xenograft glioma tumors in vivo only in the presence of intact cell-mediated immunity[1].
References:
[1]. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. [2]. Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human bridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med potheses. 2013 Sep;81(3):489-95.